DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase
gene polymorphism determines response and toxicity of
5-FU chemotherapy. Pharmacogenomics J, 2001, 1:65–70.
Ramaswamy S, Ross KN, Lander, ES, Golub TR. A molecular
signature of metastasis in primary solid tumors. Nat Genet,
2003, 33:49–54.
Roberts TG Jr, Chabner BA. Beyond fast track for drug
approvals. N Engl J Med, 2004, 351:501–505.
Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance
in the obese. J Clin Oncol, 1988, 6:1321–1327.
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant
chemotherapy for operable HER2-positive breast cancer.
N Engl J Med, 2005, 353:1673–1684.
Sawyer M, Ratain MJ. Body surface area as a determinant of
pharmacokinetics and drug dosing. Invest New Drugs, 2001,
19:171–177.
Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment
outcome with adjuvant tamoxifen relative to patient CYP2D6
and CYP2C19 genotypes. J Clin Oncol, 2007, 25:5187–5193.
Sequist LV, Lynch TJ. EGFR tyrosine kinase inhibitors in lung
cancer: An evolving story. Annu Rev Med, 2008, 59:429–442.
Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer.
N Engl J Med, 2009, 360:790–800.
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy
plus a monoclonal antibody against HER2 for metastatic
breast cancer that overexpresses HER2. N Engl J Med, 2001,
344:783–792.
Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab,
and cetuximab in metastatic colorectal cancer. N Engl J Med,
2009, 360:563–572.
Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH.
High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine
dehydrogenase gene of patients with severe
5-fluorouracil-associated toxicity. Pharmacogenetics, 2002,
12:555–558.
Weinstein IB, Joe AK. Mechanisms of disease: Oncogene
addiction—a rationale for molecular targeting in cancer therapy.
Nat Clin Pract Oncol, 2006, 8:448–457.
1675
CHAPTER 60
GENERAL PRINCIPLES OF CANCER CHEMOTHERAPY